Wahsed microbiota transplantation (WMT) is a novel and promising therapeutic method for Chronic Kidney Disease (CKD). This clinical trail aims to evaluate the efficacy and safety of WMT in the treatment of CKD.
Although the therapeutic methods progress, numerous patients with Chronic Kidney Disease (CKD) can not avoid the clinical outcome of end-stage renal disease. CKD still needs novel treatment to significantly improve the survival quality of the patients. Gut microbiota has been verified to have relation with immunity. Immunity plays a role in many chronic kidney disease, such as IgA nephropathy, membranous nephropathy and so on. Fecal microbiota transplantation (FMT) is a novel, safe, convenient therapeutic treatment which transplant gut microbiota from donor to patient to rebuild a gut microecology. This study aims to evaluate the efficacy and safety of FMT in CKD patients. Patients in this study will undergo three times WMT. The primary outcome measure was the clinical remission efficacy rate in the CKD patients. The secondary outcome measure was the safety of WMT in CKD.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
100
Biologically active human fecal fluid (donor stool) is provided in fluid form.
Patients accepted oral drug or dialytic therapy like they used to be to treat CKD.
the Second Affiliated of Nanjing Medical University
Nanjing, Jiangsu, China
RECRUITINGChanges in Blood Creatinine
Patients' Laboratory Change from Baseline Blood Creatinine
Time frame: 1 week, 4 week, 12 week
Changes in 24-hour Urine Protein
Patients' Laboratory Change from Changes in 24-hour urine protein
Time frame: 1 week, 4 week, 12 week
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.